Orphan Drug Production

• 

  Subject Areas on Research

  • Aerosolized ribavirin: the most expensive drug for pneumonia. 
  • Assessing the economic challenges posed by orphan drugs. 
  • Congress, the FDA, and the fair development of new medications for children. 
  • Developing drugs for developing countries. 
  • Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. 
  • Ethical considerations in design of a study to evaluate a US Food and Drug Administration-approved indication: antivenom versus placebo for copperhead envenomation. 
  • Gaucher disease. Current issues in diagnosis and treatment. NIH Technology Assessment Panel on Gaucher Disease. 
  • Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention. 
  • Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. 
  • Priorities for the Priority Review Voucher. 
  • Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases. 
  • Repairing the broken market for antibiotic innovation. 
  • Should the patent system for new medicines be abolished? 
  • The Commercial Market For Priority Review Vouchers. 
  • The distribution of sales revenues from pharmaceutical innovation. 
  • The quantity and quality of worldwide new drug introductions, 1982-2003. 
  • The roles of patents and research and development incentives in biopharmaceutical innovation.